Use of alemtuzumab in B-cell chronic lymphocytic leukaemia: Belgian recommendations

During a meeting on chronic lymphocytic leukaemia (CLL) in Brussels in May 2010, experts from the main departments of Haematology in Belgium met to discuss and create guidelines concerning the use of alemtuzumab (MabCampath®) in the treatment of CLL. The moderator of the meeting was Professor Dominique Bron. The objective of the meeting was to answer the following four questions with respect to the Belgian situation:
1) The place of alemtuzumab in the treatment of CLL.
2) The dose and route of administration of alemtuzumab.
3) Duration of treatment with alemtuzumab.
4) Patient management issues linked to the use of alemtuzumab.

Jaar van publicatie:2011

Trefwoorden:alemtuzumab, Belgian guidelines,, chronic lymphocytic leukaemia